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The expression ‘broad-spectrum antibiotic’ was used 
in the mid-l950s, when the bacterial spectrum of 
chloramphenicol and the first tetracyclines could be 
strikingly opposed to the narrow spectrum of activities 
of penicillin G, and streptomycin. In the 1960s, amino- 
penicillins, then ureidopenicillins, became the broad- 
spectrum penicillins in comparison with penicillin G. 
Until then, the quality of being broad spectrum or 
narrow spectrum was given to an antibiotic only when 
referring to a comparator. Later, the reference to a 
comparator was omitted, and broad and narrow lost 
their relativities and became independent character- 
istics of a compound, used with different meaning and 
often improperly. 
Never, to my knowledge, was any effort made to 
define those words. O n  what segment(s) of the range 
of bacterial species (Gram-positive cocci and bacilli, 
Enterobacteriaceae, non-fermentative Gram-negative 
rods, anaerobes, intracellular pathogens) is the classifica- 
tion as broad- or narrow-spectrum antibiotics to be 
based? O n  the narrow side, some compounds are 
narrower than others (e.g. macrolides versus metro- 
nidazole), while on the broad side, many antibiotics are 
narrower than the very broad ones (e.g. tetracyclines are 
broader than tazocillin, which is broader than cephalo- 
sporins, etc.). I will not attempt now to propose any 
definition of what is narrow and what is broad. I would 
like only to draw attention to the overuse of such 
ambiguous labels for different and even contradictory 
purposes. In my experience, this consideration justifies 
ceasing to use them. 
Broad spectrum as an expression of greater thera- 
peutic security has mainly been used by the pharma- 
ceutical industry. Most antibiotics are prescribed 
empirically on a presumptive diagnosis. This implies 
that several bacterial species are possible causes of the 
disease. It is correct that a broad-spectrum antibiotic 
may offer a better chance of covering the causative 
microorganisms. In the same way, a broad-spectrum 
agent is indicated in a large number of clinical situations. 
Recently, the trend in the pharmaceutical industry 
has been to replace the concept of broad-spectrum 
agents by organ- or system-targeted agents. The 
empirical choice of an antibiotic is determined by 
the organ or system in which the infection is located. 
This approach integrates the pharmacokinetic pro- 
perties and the activity against the more frequent 
bacteria encountered in the particular location of 
the infection. Antibiotics suitable for urinary tract 
infections, respiratory infections, digestive tract iri- 
fections, etc., have been developed. Progress can be 
expected from new compounds, and improved clinical 
approaches for the therapeutic decisions. 
The idea of broad-spectrum agents as broad 
selectors for microbial resistance, although it has a 
convincing mechanistic simplicity, has never been docu- 
mented. Bacteria resistant to an antibiotic (naturally or 
by an acquired mechanism) are normally selected by 
the agent or by another agent with a similar spectrum 
or a similar mechanism of resistance. Recent studies 
indicate that the emergence of resistance genes, their 
prevalence in one or more species and their spread 
(clonally, or as genes) are distinct phenomena. These 
are complex problems in which many factors are 
involved, such as: the size and the composition of the 
ecological niche considered; the number of species 
and the size of their populations; the quantity of the 
selecting agents (antibiotics and other antimicrobials); 
the duration of the selection pressure; the pre-existence 
of low level resistant microorganisms able to survive the 
concentrations of antibiotics present in the niche; the 
time of observation; and so on. The ability to select 
resistant organisms is not related to the breadth of the 
bacterial spectrum of an antibiotic. It is related to the 
mechanisms of resistance to that particular antibiotic 
and to several other factors already mentioned. 
The term narrow-spectrum agent is sometimes 
considered to be a synonym of targeted-microorganism 
therapy and an indicator of a physician’s competence 
and concern for ecology. As focused a diagnosis of 
an infection as possible must direct the therapeutic 
decision to the most appropriate conipound(s). The 
appropriate treatment(s) of an infection are those 
that have been proven to cure patients with similar 
infections. The appropriate antibiotic treatment is 
never defined by its antibacterial spectrum. Who 
cares about the spectrum when chloramphenicol or 
ceftriaxone is prescribed to cure enteric fever? 
I should like finally to call attention to many 
guidelines where, without adequate explanation or for 
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unacceptable reasons, it is suggested that narrow- 
spectrum antibiotics should be used. It may be asserted 
that they are less likely to select resistant bacteria. This 
statement is wrong. There are more naturally resistant 
species to narrow-spectrum than to broad-spectrum 
antibiotics and the quickest selection occurs among 
naturally resistant species. It is true that they are more 
microorganism-targeted but are they the appropriate 
treatment? It can be said that they save money, as more 
so-called broad-spectrum agents have been developed 
in recent years, and older compounds are cheapest. 
Moreover, the label of broad or narrow is given 
arbitrarily; cephalosporins are in fact narrow-spectrum 
antibiotics (especially when compared with other p- 
lactanis) with a limited activity against staphylococci 
(no activity against MRSA) or enterococci, no activity 
against more anaerobes (apart from the cephamycins), 
no activity against intracellular pathogens, variable 
activity against non-fermentative organisms. 
Many other examples could readily be found to 
illustrate the misuse of the two adjectives, broad and 
narrow, applied to the spectrum of antibiotics. It would 
be advisable to give up such categorization. Perhaps we 
should base our mental concept of an antibiotic first on 
its clinical indications and targeted organs and secondly, 
rather than on its spectrum, on the niicroorganisms not 
included in its spectrum, and on those which have 
recently acquired a mechanisni of resistance to it. 
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